Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus Statement

Johan F K F Ilvemark 1, Tawnya Hansen 2, Thomas M Goodsall 3 4, Jakob B Seidelin 1, Heba Al-Farhan 5, Mariangela Allocca 6 7, Jakob Begun 8, Robert V Bryant 9, Dan Carter 10, Britt Christensen 11, Marla C Dubinsky 12, Krisztina B Gecse 13, Torsten Kucharzik 14, Cathy Lu 15, Christian Maaser 16, Giovanni Maconi 17, Kim Nylund 18 19, Carolina Palmela 20, Stephanie R Wilson 21, Kerri Novak 15, Rune Wilkens 22 23

Affiliations

10 May 2022

-

doi: 10.1093/ecco-jcc/jjab173

Abstract

Background and aims: No consensus exists on defining intestinal ultrasound response, transmural healing, or transmural remission in inflammatory bowel disease, nor clear guidance for optimal timing of assessment during treatment. This systematic review and expert consensus study aimed to define such recommendations, along with key parameters included in response reporting.

Methods: Electronic databases were searched from inception to July 26, 2021, using pre-defined terms. Studies were eligible if at least two intestinal ultrasound [IUS] assessments at different time points during treatment were reported, along with an appropriate reference standard. The QUADAS-2 tool was used to examine study-level risk of bias. An international panel of experts [n = 18] rated an initial 196 statements [RAND/UCLA process, scale 1-9]. Two videoconferences were conducted, resulting in additional ratings of 149 and 13 statements, respectively.

Results: Out of 5826 records, 31 full-text articles, 16 abstracts, and one research letter were included; 83% [40/48] of included studies showed a low concern of applicability, and 96% [46/48] had a high risk of bias. A consensus was reached on 41 statements, with clear definitions of IUS treatment response, transmural healing, transmural remission, timing of assessment, and general considerations when using intestinal ultrasound in inflammatory bowel disease.

Conclusions: Response criteria and time points of response assessment varied between studies, complicating direct comparison of parameter changes and their relation to treatment outcomes. To ensure a unified approach in routine care and clinical trials, we provide recommendations and definitions for key parameters for intestinal ultrasound response, to incorporate into future prospective studies.

Keywords: Intestinal ultrasound; inflammatory bowel disease; transmural healing; transmural remission; treatment response.

References

  1.  
    1. Maaser C, Sturm A, Vavricka SR, et al. ; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD. Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 2019;13:144–64. - PubMed
  2.  
    1. Bryant RV, Friedman AB, Wright EK, et al. Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application. Gut 2018;67:973–85. - PubMed
  3.  
    1. Rajagopalan A, Sathananthan D, An YK, et al. Gastrointestinal ultrasound in inflammatory bowel disease care: Patient perceptions and impact on disease-related knowledge. JGH Open 2020;4:267–72. - PMC - PubMed
  4.  
    1. Smith RL, Taylor KM, Friedman AB, Gibson RN, Gibson PR. Systematic review: clinical utility of gastrointestinal ultrasound in the diagnosis, assessment, and management of patients with ulcerative colitis. J Crohns Colitis 2020;14:465–79. - PubMed
  5.  
    1. Dong J, Wang H, Zhao J, et al. Ultrasound as a diagnostic tool in detecting active Crohn’s disease: a meta-analysis of prospective studies. Eur Radiol 2014;24:26–33. - PubMed
  6.  
    1. Maconi G, Nylund K, Ripolles T, et al. EFSUMB Recommendations and Clinical Guidelines for Intestinal Ultrasound [GIUS] in Inflammatory Bowel Diseases. Ultraschall Med 2018;39:304–17. - PubMed
  7.  
    1. Goodsall TM, Nguyen TM, Parker CE, et al. Systematic review: Gastrointestinal ultrasound scoring indices for inflammatory bowel disease. J Crohns Colitis 2021;15:609–14. - PubMed
  8.  
    1. Wilkens R, Novak KL, Maaser C, Panaccione R, Kucharzik T. Relevance of monitoring transmural disease activity in patients with Crohn’s disease: current status and future perspectives. Therap Adv Gastroenterol 2021;14:17562848211006672. - PMC - PubMed
  9.  
    1. Turner D, Ricciuto A, Lewis A, et al. ; International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease [STRIDE] Initiative of the International Organization for the Study of IBD [IOIBD]: Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021;160:1570–83. - PubMed
  10.  
    1. Fitch K, Aguilar S, Burnand M, LaCalle B. The RAND/UCLA Appropriateness Method User’s Manual. Santa Monica, CA: Rand; 2001.
  11.  
    1. Veritas Health Innovation. Covidence Systematic Review Software. 2019. www.covidence.org . Accessed April 2019.
  12.  
    1. Bots S, Nylund K, Löwenberg M, Gecse K, Gilja OH, D’Haens G. Ultrasound for assessing disease activity in IBD patients: a systematic review of activity scores. J Crohns Colitis 2018;12:920–9. - PubMed
  13.  
    1. Whiting PF, Rutjes AW, Westwood ME, et al. ; QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–36. - PubMed
  14.  
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture [REDCap] – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81. - PMC - PubMed
  15.  
    1. Harris PA, Taylor R, Minor BL, et al. ; REDCap Consortium. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019;95:103208. - PMC - PubMed
  16.  
    1. Paredes JM, Moreno N, Latorre P, et al. Clinical impact of sonographic transmural healing after anti-TNF antibody treatment in patients with Crohn’s disease. Dig Dis Sci 2019;64:2600–6. - PubMed
  17.  
    1. Paredes JM, Ripollés T, Cortés X, et al. Abdominal sonographic changes after antibody to tumor necrosis factor [anti-TNF] alpha therapy in Crohn’s Disease. Dig Dis Sci 2010;55:404–10. - PubMed
  18.  
    1. Castiglione F, Testa A, Rea M, et al. Transmural healing evaluated by bowel sonography in patients with Crohn’s disease on maintenance treatment with biologics. Inflamm Bowel Dis 2013;19:1928–34. - PubMed
  19.  
    1. Castiglione F, Mainenti P, Testa A, et al. Cross-sectional evaluation of transmural healing in patients with Crohn’s disease on maintenance treatment with anti-TNF alpha agents. Dig Liver Dis 2017;49:484–9. - PubMed
  20.  
    1. Kucharzik T, Wittig BM, Helwig U, et al. ; TRUST study group. Use of intestinal ultrasound to monitor Crohn’s disease activity. Clin Gastroenterol Hepatol 2017;15:535–42.e2. - PubMed
  21.  
    1. Ripollés T, Paredes JM, Martínez-Pérez MJ, et al. Ultrasonographic changes at 12 weeks of anti-TNF drugs predict 1-year sonographic response and clinical outcome in Crohn’s disease: a multicenter study. Inflamm Bowel Dis 2016;22:2465–73. - PubMed
  22.  
    1. Ripollés T, Martínez MJ, Barrachina MM. Crohn’s disease and color Doppler sonography: response to treatment and its relationship with long-term prognosis. J Clin Ultrasound 2008;36:267–72. - PubMed
  23.  
    1. Dubbins PA. Ultrasound demonstration of bowel wall thickness in inflammatory bowel disease. Clin Radiol 1984;35:227–31. - PubMed
  24.  
    1. Onali S, Calabrese E, Petruzziello C, et al. Endoscopic vs ultrasonographic findings related to Crohn’s disease recurrence: a prospective longitudinal study at 3 years. J Crohns Colitis 2010;4:319–28. - PubMed
  25.  
    1. Moreno N, Ripollés T, Paredes JM, et al. Usefulness of abdominal ultrasonography in the analysis of endoscopic activity in patients with Crohn’s disease: changes following treatment with immunomodulators and/or anti-TNF antibodies. J Crohns Colitis 2014;8:1079–87. - PubMed
  26.  
    1. Orlando S, Coletta M, Fraquelli M, et al. Ultrasound elasticity imaging predicts therapeutic outcome in patients with crohn’s disease treated with anti-tumor necrosis factor antibodies. Dig Liver Dis 2017;49:e98. - PubMed
  27.  
    1. Socaciu M, Ciobanu L, Diaconu B, Hagiu C, Seicean A, Badea R. Non-invasive assessment of inflammation and treatment response in patients with Crohn’s disease and ulcerative colitis using contrast-enhanced ultrasonography quantification. J Gastrointestin Liver Dis 2015;24:457–65. - PubMed
  28.  
    1. Goertz RS, Klett D, Wildner D, Atreya R, Neurath MF, Strobel D. Quantitative contrast-enhanced ultrasound for monitoring vedolizumab therapy in inflammatory bowel disease patients: a pilot study. Acta Radiol 2018;59:1149–56. - PubMed
  29.  
    1. Quaia E, Gennari AG, Cova MA. Early predictors of the long-term response to therapy in patients with Crohn disease derived from a time-intensity curve analysis after microbubble contrast agent injection. J Ultrasound Med 2019;38:947–58. - PubMed
  30.  
    1. Saevik F, Nylund K, Hausken T, Ødegaard S, Gilja OH. Bowel perfusion measured with dynamic contrast-enhanced ultrasound predicts treatment outcome in patients with Crohn’s disease. Inflamm Bowel Dis 2014;20:2029–37. - PMC - PubMed
  31.  
    1. Chen JM, He LW, Yan T, et al. Oral exclusive enteral nutrition induces mucosal and transmural healing in patients with Crohn’s disease. Gastroenterol Rep [Oxf] 2019;7:176–84. - PMC - PubMed
  32.  
    1. Hoffmann P, Krisam J, Wehling C, et al. Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease. World J Gastroenterol 2019;25:4481–92. - PMC - PubMed
  33.  
    1. Zorzi F, Ghosh S, Chiaramonte C, et al. Response assessed by ultrasonography as target of biological treatment for Crohn’s Disease. Clin Gastroenterol Hepatol 2020;18:2030–7. - PubMed
  34.  
    1. Calabrese E, Rispo A, Zorzi F, et al. Ultrasonography tight control and monitoring in Crohn’s disease during different biological therapies: a multicenter study. Clin Gastroenterol Hepatol 2021. Doi: 10.1016/j.cgh.2021.03.030. - DOI - PubMed
  35.  
    1. Hoffmann T, Fusco S, Blumenstock G, Sadik S, Malek NP, Froehlich E. Evaluation of bowel wall thickness by ultrasound as early diagnostic tool for therapeutic response in Crohn’s disease patients treated with ustekinumab. Z Gastroenterol 2020. Doi: 10.1055/a-1283-6550. - DOI - PubMed
  36.  
    1. Ma L, Li W, Zhuang N, et al. Comparison of transmural healing and mucosal healing as predictors of positive long-term outcomes in Crohn’s disease. Therap Adv Gastroenterol 2021;14:17562848211016259. - PMC - PubMed
  37.  
    1. Helwig U, Fischer I, Hammer L, et al. Transmural response and transmural healing defined by intestinal ultrasound—new potential therapeutic targets? J Crohns Colitis 2022;16:57–67. - PubMed
  38.  
    1. Jessen B, Rodriguez-Sillke Y, Sonnenberg E, et al. Level of tumor necrosis factor production by stimulated blood mononuclear cells can be used to predict response of patients with inflammatory bowel diseases to infliximab. Clin Gastroenterol Hepatol 2021;19:721–31.e1. - PubMed
  39.  
    1. Parente F, Molteni M, Marino B, et al. Are colonoscopy and bowel ultrasound useful for assessing response to short-term therapy and predicting disease outcome of moderate-to-severe forms of ulcerative colitis?: a prospective study. Am J Gastroenterol 2010;105:1150–7. - PubMed
  40.  
    1. Maaser C, Petersen F, Helwig U, et al. ; German IBD Study Group and the TRUSTandUC Study Group.. Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUSTandUC study. Gut 2020;69:1629–36. - PMC - PubMed
  41.  
    1. Maconi G, Ardizzone S, Parente F, Bianchi Porro G. Ultrasonography in the evaluation of extension, activity, and follow-up of ulcerative colitis. Scand J Gastroenterol 1999;34:1103–7. - PubMed
  42.  
    1. Yoshida A, Kobayashi K, Ueno F, et al. Possible role of early transabdominal ultrasound in patients undergoing cytapheresis for active ulcerative colitis. Intern Med 2011;50:11–5. - PubMed
  43.  
    1. Hean R, Su H, Taylor K, et al. The value of gastrointestinal ultrasound in predicting sonographic remission to vedolizumab: A step towards individualized biological therapy of inflammatory bowel disease [abstract]. J Gastroenterol Hepatol 2019;34: 157–8.
  44.  
    1. Maaser C, Petersen F, Helwig U, et al. Monitoring response to anti-TNF therapy in ulcerative colitis patients by gastrointestinal ultrasound: sub-analysis from TRUSTandUC [abstract]. J Crohns Colitis 2019;13:S063–4.
  45.  
    1. Arienti V, Campieri M, Boriani L, et al. Management of severe ulcerative colitis with the help of high resolution ultrasonography. Am J Gastroenterol 1996;91:2163–9. - PubMed
  46.  
    1. de Voogd F, Van Wassenaer E, Mookhoek A, et al. Decrease in bowel wall thickness at intestinal ultrasound accurately detects early endoscopic remission and improvement in ulcerative colitis patients on tofacitinib: a longitudinal prospective cohort study [abstract]. J Crohns Colitis 2021;15:S315–7.
  47.  
    1. Kucharzik T, Helwig U, Seibold F, et al. Improvement of intestinal ultrasound parameters within 12 weeks after treatment induction in CD and UC patients—first interim analysis of the trust beyond study [abstract]. United Eur Gastroenterol J 2020;8:356.
  48.  
    1. Maaser C, Helwig U, Fischer I, Rath S, Kolterer S, Kucharzik T. Patient-Reported Outcomes [PRO-2] and intestinal ultrasound in ulcerative colitis patients—subanalysis of the TRUSTandUC study cohort [abstract]. Gastroenterology 2020;158:694.
  49.  
    1. Nylund K, Maconi G, Hollerweger A, et al. EFSUMB Recommendations and Guidelines for Gastrointestinal Ultrasound. Ultraschall Med 2017;38:e1–e15. - PubMed
  50.  
    1. Nylund K, Hausken T, Ødegaard S, Eide GE, Gilja OH. Gastrointestinal wall thickness measured with transabdominal ultrasonography and its relationship to demographic factors in healthy subjects. Ultraschall Med 2012;33:E225–32. - PubMed
  51.  
    1. Zink F, Kratzer W, Schmidt S, et al. Comparison of two high-end ultrasound systems for contrast-enhanced ultrasound quantification of mural microvascularity in Crohn’s Disease. Ultraschall Med 2016;37:74–81. - PubMed
  52.  
    1. Bouguen G, Levesque BG, Pola S, Evans E, Sandborn WJ. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn’s disease. Clin Gastroenterol Hepatol 2014;12:978–85. - PubMed
  53.  
    1. Vasudevan A, Gibson PR, van Langenberg DR. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? World J Gastroenterol 2017;23:6385–402. - PMC - PubMed
  54.  
    1. Ordás I, Rimola J, Rodríguez S, et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn’s disease. Gastroenterology 2014;146:374–82.e1. - PubMed
  55.  
    1. Scarallo L, Maniscalco V, Paci M, et al. Bowel ultrasound scan predicts corticosteroid failure in children with acute severe colitis. J Pediatr Gastroenterol Nutr 2020;71:46–51. - PubMed
  56.  
    1. Dillman JR, Dehkordy SF, Smith EA, et al. Defining the ultrasound longitudinal natural history of newly diagnosed pediatric small bowel Crohn disease treated with infliximab and infliximab-azathioprine combination therapy. Pediatr Radiol 2017;47:924–34. - PMC - PubMed
  57.  
    1. Kucharzik T, Wilkens R, Maconi G, et al. Intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn’s disease: Week 16 interim analysis of the STARDUST trial substudy [abstract]. J Crohns Colitis 2020;14:S046–8.
  58.  
    1. Kucharzik T, Wilkens R, Maconi G, et al. Intestinal ultrasound response and transmural healing after 48 weeks of treatment with ustekinumab in Crohn’s disease: STARDUST Trial sub-study [abstract]. United Eur Gastroenterol J 2020;8:1258–75.
  59.  
    1. Civitelli F, Nuti F, Oliva S, et al. Looking beyond mucosal healing: effect of biologic therapy on transmural healing in pediatric Crohn’s Disease. Inflamm Bowel Dis 2016;22:2418–24. - PubMed
  60.  
    1. Moreno Sánchez N, Paredes JM, Ripollés T, et al. Treatment of abdominal fistulas in Crohn’s disease and monitoring with abdominal ultrasonography. Rev Esp Enferm Dig 2021;113:240–5. - PubMed
  61.  
    1. Choi J, Phan B, Dubinsky M, Rosenberg H. Use of small bowel ultrasound to predict response to infliximab induction [abstract]. Pediatr Radiol 2018;48:S80. - PubMed
  62.  
    1. Novak KL, Nylund K, Maaser C, et al. Expert consensus on optimal acquisition and development of the International Bowel Ultrasound Segmental Activity Score [IBUS-SAS]: a reliability and inter-rater variability study on intestinal ultrasonography in Crohn’s Disease. J Crohns Colitis 2020;15: 609–16. - PMC - PubMed
  63.  
    1. Novak KL, Kaplan GG, Panaccione R, et al. A simple ultrasound score for the accurate detection of inflammatory activity in Crohn’s Disease. Inflamm Bowel Dis 2017;23:2001–10. - PubMed
  64.  
    1. Sævik F, Eriksen R, Eide GE, Gilja OH, Nylund K. Development and validation of a simple ultrasound activity score for Crohn’s Disease. J Crohns Colitis 2021;15:115–24. - PMC - PubMed
  65.  
    1. Kunihiro K, Hata J, Haruma K, Manabe N, Tanaka S, Chayama K. Sonographic detection of longitudinal ulcers in Crohn disease. Scand J Gastroenterol 2004;39:322–6. - PubMed
  66.  
    1. Ripollés T, Poza J, Suarez Ferrer C, Martínez-Pérez MJ, Martín-Algíbez A, de Las Heras Paez B. Evaluation of Crohn’s disease activity: development of an ultrasound score in a multicenter study. Inflamm Bowel Dis 2021;27:145–54. - PubMed
  67.  
    1. Bots S, Nylund K, Löwenberg M, Gecse K, D’Haens G. Intestinal ultrasound to assess disease activity in ulcerative colitis: development of a novel UC-Ultrasound index. J Crohns Colitis 2021;15:877–8. - PMC - PubMed
  68.  
    1. De Voogd F, Wilkens R, Gecse K, et al. A reliability study: strong inter-observer agreement of an expert panel for intestinal ultrasound in ulcerative colitis. J Crohns Colitis 2021;15:1284–90. - PMC - PubMed
  69.  
    1. Ordás I, Rimola J, Alfaro I, et al. Development and validation of a simplified magnetic resonance index of activity for Crohn’s Disease. Gastroenterology 2019;157:432–9.e1. - PubMed
  70.  
    1. Liu C, Ding SS, Zhang K, et al. Correlation between ultrasound consolidated score and simple endoscopic score for determining the activity of Crohn’s disease. Br J Radiol 2020;93:20190614. - PMC - PubMed
  71.  
    1. Marin AM, Calapod OP, Moldoveanu AC, Tribus LC, Fierbințeanu-Braticevici C. Non-invasive ultrasonographic score for assessment of the severity of inflammatory bowel disease. Ultrasound Med Biol 2021;47:932–40. - PubMed
  72.  
    1. Ma H, Isaac DM, Petrova A, et al. Validation of a modified simple ultrasound activity score for children with Crohn’s disease [abstract]. In: Proceedings of the 16th ECCO Congress; July 2-3 and 8-10 2021; virtual.
  73.  
    1. Van Wassenaer E, Benninga MA, Koot BGP, et al. The development of the PCD-US: The Pediatric Crohn’s Disease intestinal Ultrasound Score. J Pediatr Gastroenterol Nutr 2021;72:90.
  74.  
    1. Allocca M, Filippi E, Costantino A, et al. Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation. United European Gastroenterol J 2021;9:438–42. - PMC - PubMed
  75.  
    1. Zhang M, Zhang H, Zhu Q, et al. Bowel ultrasound enhances predictive value based on clinical indicators: a scoring system for moderate-to-severe endoscopic activities in patients with ulcerative colitis. Therap Adv Gastroenterol 2021;14:17562848211030050. - PMC - PubMed
  76.  
    1. Halasz J, Lu C, Kaplan G, et al. Early 12-week ultrasound response to treatment, used as a predictor of response at 6 months in Crohn’s disease: A prospective cohort study [abstract]. J Crohns Colitis 2018;12:S384.
  77.  
    1. Di Fluri G, Ceccarelli L, Ricchiuti A, et al. Role of contrast-enhanced ultrasonography [CEUS] in assessment of inflammatory activity in patients with small bowel crohn’s disease [abstract]. Gastroenterology 2013;144:S423.
  78.  
    1. Wilkens R, Lu C, Novak KL, et al. Which ultrasound change occurs most quickly in response to treatment in Crohn’s disease: Reduction in bowel wall thickness or mural perfusion? [abstract]. United Eur Gastroenterol J 2019;6:621–2.
  79.  
    1. Limberg B. [Diagnosis of chronic inflammatory bowel disease by ultrasonography]. Z Gastroenterol 1999;37:495–508. - PubMed
  80.  
    1. Yasuhara H, Kunisaki R, Tsunoda S, et al. Early transabdominal ultrasonography to assess intestinal wall thickness and vascularity appears to predict long-term outcome in Crohn’s disease patients undergoing infliximab therapy: A prospective study [abstract]. J Crohns Colitis 2015;9:S19–20.
  81.  
    1. Fraquelli M, Branchi F, Cribiù FM, et al. The role of ultrasound elasticity imaging in predicting ileal fibrosis in crohn’s disease patients. Inflamm Bowel Dis 2015;21:2605–12. - PubMed
  82.  
    1. Kucharzik T, Maaser C, Helwig U, et al. Monitoring response to adalimumab therapy in Crohn’s disease patients by bowel ultrasound: sub-analysis from TRUST [abstract]. J Crohns Colitis 2018;12:S319.
  83.  
    1. Castiglione F, Imperatore N, Testa A, et al. One-year clinical outcomes with biologics in Crohn’s disease: transmural healing compared with mucosal or no healing. Aliment Pharmacol Ther 2019;49:1026–39. - PubMed
  84.  
    1. Geyl S, Guillo L, Laurent V, D’Amico F, Danese S, Peyrin-Biroulet L. Transmural healing as a therapeutic goal in Crohn’s disease: a systematic review. Lancet Gastroenterol Hepatol 2021. Doi: 10.1016/S2468-1253[21]00096-0. - DOI - PubMed
  85.  
    1. Goodsall TM, Jairath V, Feagan BG, et al. Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn’s disease. Aliment Pharmacol Ther 2021;53:873–86. - PubMed
  86.  
    1. Sagami S, Kobayashi T, Miyatani Y, et al. Accuracy of ultrasound for evaluation of colorectal segments in patients with inflammatory bowel diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2021;19:908–21.e6. - PubMed
  87.  
    1. Gomes CF, Nascimento CN, Pereira F, et al. Use of bowel ultrasound to assess disease activity in Crohn’s disease patients after induction therapy with infliximab [abstract]. J Crohn’s Colitis 2020;14:S431.
  88.  
    1. Civitelli F, Oliva S, Cersosimo K, et al. Long-term impact of transmural healing on the clinical outcome of pediatric Crohn’s disease [abstract]. Dig Liver Dis 2017;49:e263.
  89.  
    1. Wilkens R, Hagemann-Madsen RH, Peters DA, et al. Validity of contrast-enhanced ultrasonography and dynamic contrast-enhanced MR enterography in the assessment of transmural activity and fibrosis in Crohn’s disease. J Crohns Colitis 2018;12:48–56. - PubMed
  90.  
    1. Maconi G, Greco S, Duca P, et al. Prevalence and clinical significance of sonographic evidence of mesenteric fat alterations in Crohn’s disease. Inflamm Bowel Dis 2008;14:1555–61. - PubMed
  91.  
    1. Smith RL, Taylor KM, Friedman AB, Swaine AP, Gibson DJ, Gibson PR. Early assessment with gastrointestinal ultrasound in patients hospitalised for a flare of ulcerative colitis and predicting the need for salvage therapy: a pilot study. Ultrasound Med Biol 2021;47:1108–14. - PubMed
  92.  
    1. Haber HP, Busch A, Ziebach R, Stern M. Bowel wall thickness measured by ultrasound as a marker of Crohn’s disease activity in children [research letter]. Lancet 2000;355:1239–40. - PubMed
  93.  
    1. Dolinger MT, Choi JJ, Phan BL, Rosenberg HK, Rowland J, Dubinsky MC. Use of small bowel ultrasound to predict response to infliximab induction in pediatric Crohn’s Disease. J Clin Gastroenterol 2021;55:429–32. - PubMed
  94.  
    1. Peyrin-Biroulet L, Panés J, Sandborn WJ, et al. Defining disease severity in inflammatory bowel diseases: current and future directions. Clin Gastroenterol Hepatol 2016;14:348–54.e17. - PubMed
  95.  
    1. Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut 2014;63:88–95. - PubMed

Page Navigation